Content area

|
|

Ny behandling af kronisk hepatitis B

Forfatter(e)
Reservelæge Ellen Sloth Andersen & afdelingslæge Nina M. Weis Hvidovre Hospital, Infektionsmedicinsk Afdeling
Reference: 
Ugeskr Læger 2008;170(48):3937-3939
Blad nummer: 
Sidetal: 
3937-3939
Summary New treatment of chronic hepatitis B Ugeskr Læger 2008;170(48):3937-3939 Worldwide, 350 million people are infected with chronic hepatitis B. Over the last few years, it has been possible to treat chronic hepatitis B. Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated α -interferon. In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B. In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Knud Raben-Pedersen | 21/09
6 kommentarer
af Peter Matzen | 21/09
1 Kommentar
af Finn Vallø Hansen | 21/09
1 Kommentar
af Johan Ludvig Reventlow | 19/09
2 kommentarer
af Andreas Gothardt Lundh | 17/09
1 Kommentar
af Bjørn Søeberg | 17/09
33 kommentarer
af Lene Annette Norberg | 15/09
5 kommentarer
af Søren Holm | 14/09
1 Kommentar